PetMed Express, Inc. (NASDAQ:PETS) Director Ronald J. Korn sold 2,000 shares of PetMed Express stock in a transaction dated Thursday, December 24th. The shares were sold at an average price of $34.00, for a total transaction of $68,000.00. Following the completion of the transaction, the director now directly owns 85,333 shares of the company’s stock, valued at approximately $2,901,322. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.
PetMed Express stock traded down $0.25 during midday trading on Monday, hitting $33.52. The company’s stock had a trading volume of 648,884 shares, compared to its average volume of 616,505. PetMed Express, Inc. has a 1-year low of $21.20 and a 1-year high of $42.88. The company has a 50-day moving average price of $30.37 and a two-hundred day moving average price of $32.30. The company has a market cap of $679.52 million, a price-to-earnings ratio of 23.95 and a beta of 0.70.
PetMed Express (NASDAQ:PETS) last issued its quarterly earnings data on Saturday, October 31st. The company reported $0.42 earnings per share for the quarter, topping the consensus estimate of $0.40 by $0.02. PetMed Express had a net margin of 9.41% and a return on equity of 21.91%. The business had revenue of $75.40 million during the quarter, compared to analysts’ expectations of $77.05 million. During the same quarter in the previous year, the company earned $0.33 EPS. The business’s revenue was up 7.9% on a year-over-year basis.
A number of research analysts have recently commented on PETS shares. ValuEngine downgraded shares of PetMed Express from a “hold” rating to a “sell” rating in a research report on Tuesday, November 3rd. BidaskClub raised shares of PetMed Express from a “sell” rating to a “hold” rating in a report on Thursday, December 17th.
Several large investors have recently modified their holdings of the company. American International Group Inc. raised its position in shares of PetMed Express by 2.6% in the 2nd quarter. American International Group Inc. now owns 13,886 shares of the company’s stock valued at $495,000 after buying an additional 351 shares in the last quarter. JPMorgan Chase & Co. increased its position in PetMed Express by 0.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 51,520 shares of the company’s stock worth $1,617,000 after purchasing an additional 413 shares in the last quarter. California Public Employees Retirement System increased its position in PetMed Express by 0.9% during the 2nd quarter. California Public Employees Retirement System now owns 44,026 shares of the company’s stock worth $1,569,000 after purchasing an additional 414 shares in the last quarter. Nuveen Asset Management LLC increased its position in PetMed Express by 0.7% during the 2nd quarter. Nuveen Asset Management LLC now owns 78,429 shares of the company’s stock worth $2,795,000 after purchasing an additional 555 shares in the last quarter. Finally, Cubist Systematic Strategies LLC increased its position in PetMed Express by 2.5% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 23,503 shares of the company’s stock worth $838,000 after purchasing an additional 577 shares in the last quarter. Institutional investors own 92.75% of the company’s stock.
PetMed Express Company Profile
PetMed Express, Inc, together with its subsidiaries, doing business as 1-800-PetMeds, operates as a pet pharmacy in the United States. The company markets prescription and non-prescription pet medications, and other health products for dogs, cats, and horses. It offers non-prescription medications and supplies, such as flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and supplies; and prescription medications, including heartworm preventative, flea and tick preventative, arthritis, dermatitis, thyroid, diabetes, pain medications, heart/blood pressure, and other specialty medications, as well as generic substitutes.
Read More: Why is insider trading harmful?
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]